Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non-Current Assets for 10 consecutive years, with $581.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 15.31% to $581.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, down 16.57% year-over-year, with the annual reading at $581.0 million for FY2025, 15.31% down from the prior year.
  • Non-Current Assets for Q4 2025 was $581.0 million at Ultragenyx Pharmaceutical, up from $547.2 million in the prior quarter.
  • The five-year high for Non-Current Assets was $758.8 million in Q4 2023, with the low at $526.8 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $636.0 million, with a median of $638.4 million recorded in 2021.
  • The sharpest move saw Non-Current Assets surged 60.93% in 2021, then decreased 25.92% in 2025.
  • Over 5 years, Non-Current Assets stood at $665.8 million in 2021, then decreased by 0.64% to $661.5 million in 2022, then grew by 14.71% to $758.8 million in 2023, then fell by 9.6% to $686.0 million in 2024, then dropped by 15.31% to $581.0 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $581.0 million, $547.2 million, and $586.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.